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Letters
COMMENT&RESPONSE
Cardiovascular Risk Prediction in Patients
WithHuman Immunodeficiency Virus
To the EditorWereadwith interest the article byFeinstein et al1
in the February issue of JAMA Cardiology. Despite the well-
known increased riskof cardiovasculardisease inpatientswith
human immunodeficiency virus (HIV), there do not seem
to be good prediction models to accurately estimate risk.
Feinstein et al1 noted that the accuracyof thepredictionmod-
els may be particularly low in women and Hispanic individu-
als and that the equations may work best in patients at mod-
erate to high risk. Furthermore, there was no evidence that
adding HIV-specific risk factors to algorithms based on tradi-
tional risk factors, suchas thePooledEquations, increased the
performance of these models.
Theseresultsare remarkablysimilar to thefindingswepub-
lished in2016 in aEuropean longitudinal cohort of 2550white
patients with HIV.2 Among 2550 patients with HIV (median
age, 46.5 years; 34% female), we reported a 3.98 per 1000 pa-
tient-years hard cardiovascular event rate, while Feinstein et
al1 reported an event rate of 4.4 per 1000 patient-years. Like
Feinstein et al,1 we recorded mostly myocardial infarctions
(MIs) and reported a similar and fairly low accuracy of tradi-
tionalorHIV-specificpredictionalgorithms.Feinsteinetal1 sug-
gested that consideration should be given to lowering the risk
thresholds to capture more events in the lower-risk groups.
However, even this approach was shown to be ineffective in
our publication.2 We submit that the size of the populations
studied was different, with several more events recorded by
Feinstein et al,1 but the results were the same.
Of note, another recent publication by Crane et al3 high-
lighted an important difference in the type ofMIs recorded in
thegeneralpopulationandpatientswithHIV;whileonlyabout
a quarter ofMIs are type 2 in the general population, over half
of theMIs recorded in patients with HIV are type 2. This type
ofMIhas a verydifferent pathogenesis from type 1MI, andof-
ten,plaque ruptureand intravascular acute thrombosis arenot
the mechanisms subtending the events but rather, for ex-
ample, sepsis, vasospasm due to cocaine use, anemia, and
acute volume fluctuations. In the study by Crane et al,3 these
events occurred more frequently in women and Hispanic in-
dividuals where the Pooled Equations appear to underesti-
mate cardiovascular events.Hence, itmaybe inappropriate to
use algorithms that were calibrated to predict an atheroscle-
rotic event in the general population to estimate the risk of
events that in more than half of the cases are nonatheroscle-
rotic in patients with HIV. Future studies may need to ad-
dress the calibrationof various algorithms to separate the risk
of type 1 MI from type 2 MI.
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